Share Twitter LinkedIn Facebook Email Jack Stewart, CSO of Soricimed Biopharma explains SOR-C13 is the leading drug in a phase 1b clinical trial in late stage pancreatic cancer.
Revolutionizing Pancreatic Cancer Detection: The Groundbreaking Role of Liquid Biopsies – Ajay Goel, PhD [AACR 2024] Pancreatic 3 Mins Read
